Particularly, in NSCLC, the expression level of PD-L1 is reduced by EGFR inhibitors [81–83]; however, it is upregulated in some patients with acquired resistance to EGFR inhibitors [84–86]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.